1. Home
  2. HWH vs CURX Comparison

HWH vs CURX Comparison

Compare HWH & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HWH International Inc.

HWH

HWH International Inc.

HOLD

Current Price

$1.81

Market Cap

11.0M

Sector

Health Care

ML Signal

HOLD

CURX

Curanex Pharmaceuticals Inc

HOLD

Current Price

$0.22

Market Cap

9.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWH
CURX
Founded
2021
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0M
9.4M
IPO Year
2022
2024

Fundamental Metrics

Financial Performance
Metric
HWH
CURX
Price
$1.81
$0.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
44.4K
90.2K
Earning Date
05-14-2026
09-09-2025
Dividend Yield
N/A
N/A
EPS Growth
47.37
N/A
EPS
N/A
N/A
Revenue
$866,926.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.18
52 Week High
$7.77
$9.18

Technical Indicators

Market Signals
Indicator
HWH
CURX
Relative Strength Index (RSI) 67.91 51.21
Support Level $0.97 $0.18
Resistance Level $1.81 $0.24
Average True Range (ATR) 0.14 0.02
MACD 0.03 0.01
Stochastic Oscillator 81.51 61.51

Price Performance

Historical Comparison
HWH
CURX

About HWH HWH International Inc.

HWH International Inc and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore. The Company is presently developing Hapi Marketplace, a business-to-consumer platform featuring diverse product categories, and Hapi Wealth Builder, an educational program focused on wealth-building strategies.

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.

Share on Social Networks: